Praluent Approved for Homozygous Familial Hypercholesterolemia
The approval was based on data from the phase 3 ODYSSEY HoFH trial, which evaluated Praluent in 69 adults with HoFH who were on other LDL-C-lowering therapies.
Hyperlipoproteinemias
New Drug Product: Evkeeza
This slideshow shows drug information for Evkeeza. Click here for the complete Evkeeza monograph.
ASA: Adding Icosapent Ethyl to Statin Further Cuts Stroke Risk
Event rates for time to first fatal or nonfatal stroke significantly reduced for IPE versus placebo
No Effect of Low-Dose Atorvastatin Found for Muscle Symptoms
For participants reporting muscle symptoms when taking statins, no overall effect seen for atorvastatin 20mg vs placebo
Provider Teams Outperform Solo Care for New-Onset Chronic Disease
Among solo providers, there was little difference in care management and outcomes between physicians, nonphysicians
Aspirin Overused, Statins Underused for CVD Prevention in Seniors
56.4 percent aged 75 years and older using statin for secondary cardiovascular event prevention; 45.3 percent taking aspirin for primary prevention
MPR Weekly Dose Podcast 69
An FDA warning to pharma company regarding their promo material; Entresto’s approval is expanded; There’s approvals in homozygous familial hypercholesterolemia and chronic inflammatory demyelinating polyneuropathy; And a migraine device is OK’d for teens.
Evkeeza Approved for Homozygous Familial Hypercholesterolemia
The approval was based on data from the double-blind, placebo-controlled phase 3 ELIPSE HoFH trial.
New Drugs Approved in 2020
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Inclisiran Approval Held Up by Inspection-Related Issues
Inclisiran is a chemically synthesized small interfering RNA that targets proprotein convertase subtilisin-kexin type 9 (PCSK9) messenger RNA.
